Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Nov 25, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed November 25, 2024
Period End
November 22, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed November 25, 2024. Cited figures are marked; the original filing is the authoritative source.

On November 25, 2024, BridgeBio Pharma, Inc. (BBIO) reported in a Form 8-K that the U.S. Food and Drug Administration approved Attruby (acoramidis), an oral near-complete (≥90%a) stabilizer of transthyretin (TTR), to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM.

The approval is based on the Phase 3 ATTRibute-CM study, which enrolled 632 participants randomized 2:1 to Attruby or placebo for 30 months. The trial met its primary composite endpoint with a Win Ratio of 1.8 (p<0.0001), and the filing reports a 42%b reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization relative to placebo at Month 30, and a 50% reduction in the cumulative frequency of cardiovascular-related hospitalization events. The company disclosed commercial terms in the filing.

The recommended dose is 712 mg (two 356 mg tablets) taken twice daily, with a list price of $18,759.12c for a 28-day supply. BridgeBio states that the approval triggers a $500 million payment under its royalty funding agreement. The filing also notes that the company has only recently begun establishing its sales force and commercialization capabilities, and that reimbursement, pricing and competition are key risks.

Reported adverse reactions were mostly mild: diarrhea (11.6%d vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4%), with discontinuation rates due to adverse events of 9.3% for Attruby and 8.5% for placebo. Outside the U.S., BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025, and has granted Bayer exclusive rights to commercialize acoramidis for ATTR-CM in Europe.

The company also plans to pursue approvals in Japan and Brazil. BridgeBio will provide Attruby free for life to U.S. clinical trial participants.

Key Highlights

  1. FDA approved Attruby (acoramidis) to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM, the first and only approved product with a label specifying near-complete (≥90%) TTR stabilization.
  2. Phase 3 ATTRibute-CM study (632 participants) met its primary composite endpoint with a Win Ratio of 1.8 (p<0.0001).
  3. The filing reports a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization vs. placebo at Month 30, and a 50% reduction in the cumulative frequency of cardiovascular-related hospitalization events.
  4. Approval triggers a $500 million payment to BridgeBio under its royalty funding agreement.
  5. List price is $18,759.12 for a 28-day supply at a recommended dose of 712 mg (two 356 mg tablets) taken twice daily.
  6. Most common adverse reactions were diarrhea (11.6% vs 7.6% placebo) and upper abdominal pain (5.5% vs 1.4% placebo); discontinuation rates were 9.3% for Attruby vs 8.5% for placebo.
  7. European Marketing Authorization Application submitted with a decision expected in 2025; Bayer holds exclusive European commercialization rights for acoramidis in ATTR-CM.

Frequently Asked Questions

  1. What did the FDA approve, and for which patients?

    The FDA approved Attruby (acoramidis), an orally administered near-complete (≥90%) TTR stabilizer, for adults with ATTR-CM (cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis) to reduce cardiovascular death and cardiovascular-related hospitalization.

  2. What clinical results support the approval?

    In the ATTRibute-CM Phase 3 study, the trial met its primary composite endpoint (all-cause mortality, cardiovascular-related hospitalization, NT-proBNP and 6-minute walk distance) with a Win Ratio of 1.8 (p<0.0001). The filing reports a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization vs. placebo at Month 30, and a 50% reduction in cumulative cardiovascular-related hospitalization events.

  3. What is the cost and dosing of Attruby?

    The recommended dose is 712 mg (two 356 mg tablets) taken twice daily. The list price is $18,759.12 for a 28-day supply.

  4. What financial impact does the approval have on BridgeBio?

    BridgeBio states that it will receive a $500 million payment under its royalty funding agreement upon the approval.

  5. What are the next regulatory steps and key risks?

    BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025, and plans to pursue approvals in Japan and Brazil. Bayer has exclusive rights to commercialize acoramidis for ATTR-CM in Europe. Risks cited include the company's recently begun sales force build-out, dependence on third parties, government and third-party payor reimbursement and pricing actions, and competition.